Interferon beta
Avonex, Rebif (interferon beta) is a protein pharmaceutical. Interferon beta was first approved as Avonex on 1997-03-13. It has been approved in Europe to treat multiple sclerosis. The pharmaceutical is active against interleukin-6 receptor subunit alpha and interleukin-6. In addition, it is known to target interferon alpha/beta receptor 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| avonex | Biologic Licensing Application | 2016-03-31 |
| avonex avonex avonex pen | Biologic Licensing Application | 2020-12-16 |
| avonex avonex pen | Biologic Licensing Application | 2024-11-13 |
| betaseron | Biologic Licensing Application | 2025-09-18 |
| rebif | Biologic Licensing Application | 2010-01-14 |
| rebif rebif rebidose | Biologic Licensing Application | 2025-09-22 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J1826 | Injection, interferon beta-1a, 30 mcg |
| J1830 | Injection, interferon beta-1b, 0.25 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) |
| Q3027 | Injection, interferon beta-1a, 1 mcg for intramuscular use |
| Q3028 | Injection, interferon beta-1a, 1 mcg for subcutaneous use |
Clinical
Clinical Trials
383 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 12 | 38 | 42 | 35 | 110 | 232 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | 6 | 24 | 35 | 35 | 41 | 140 |
| Sclerosis | D012598 | — | — | 4 | 17 | 10 | 18 | 45 | 92 |
| Covid-19 | D000086382 | — | U07.1 | — | 9 | 6 | 2 | 4 | 21 |
| Optic neuritis | D009902 | EFO_0007405 | H46 | — | 1 | — | 2 | — | 3 |
| Hepatitis c | D006526 | — | B19.2 | — | — | 1 | 1 | — | 2 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | — | 1 | 1 | — | 2 |
| Injection site reaction | D000075662 | — | — | — | — | — | 1 | 1 | 2 |
| Inflammation | D007249 | MP_0001845 | — | 1 | — | — | 1 | — | 2 |
| Neuritis | D009443 | — | — | — | 1 | — | 1 | — | 2 |
Show 9 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | 1 | 2 | 4 | — | 4 | 11 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | 2 | 4 | — | 2 | 7 |
| Chronic progressive multiple sclerosis | D020528 | EFO_0003840 | — | 1 | — | 1 | — | 4 | 6 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | 1 | 1 | 2 | — | 1 | 4 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | 1 | — | 1 | 3 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | — | 1 | — | 1 | 3 |
| Dermatomyositis | D003882 | EFO_0000398 | M33 | — | 1 | 2 | — | — | 3 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | 1 | — | 1 | 2 |
| Severe acute respiratory syndrome | D045169 | EFO_0000694 | J12.81 | — | — | 2 | — | — | 2 |
| Coronavirus | D017934 | — | — | — | — | 1 | — | 1 | 2 |
Show 12 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 5 | 1 | — | — | — | 5 |
| Melanoma | D008545 | — | — | 3 | 3 | — | — | — | 5 |
| Carcinoma | D002277 | — | C80.0 | 4 | 3 | — | — | — | 5 |
| Infections | D007239 | EFO_0000544 | — | — | 1 | — | — | 3 | 4 |
| Asthma | D001249 | EFO_0000270 | J45 | — | 2 | — | — | 1 | 3 |
| Merkel cell carcinoma | D015266 | EFO_1001471 | C4A | 3 | 2 | — | — | — | 3 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 3 | 1 | — | — | — | 3 |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | 3 | — | — | — | 3 |
| Cutaneous malignant melanoma | D000096142 | — | — | 1 | 1 | — | — | — | 2 |
| Non-small-cell lung carcinoma | D002289 | — | — | 2 | 1 | — | — | — | 2 |
Show 32 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 10 | — | — | — | — | 10 |
| Syndrome | D013577 | — | — | 1 | — | — | — | 2 | 3 |
| Myelodysplastic syndromes | D009190 | — | D46 | 2 | — | — | — | — | 2 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 2 | — | — | — | — | 2 |
| Multiple myeloma | D009101 | — | C90.0 | 2 | — | — | — | — | 2 |
| T-cell lymphoma | D016399 | — | — | 2 | — | — | — | — | 2 |
| Large-cell lymphoma anaplastic | D017728 | — | C84.6 | 2 | — | — | — | — | 2 |
| T-cell lymphoma peripheral | D016411 | — | — | 2 | — | — | — | — | 2 |
| Mycosis fungoides | D009182 | — | C84.0 | 2 | — | — | — | — | 2 |
| Pleural effusion | D010996 | — | J90 | 2 | — | — | — | — | 2 |
Show 47 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fatigue | D005221 | — | R53.83 | — | — | — | — | 3 | 3 |
| Communicable diseases | D003141 | — | — | — | — | — | — | 2 | 2 |
| Progressive multifocal leukoencephalopathy | D007968 | EFO_0007455 | A81.2 | — | — | — | — | 2 | 2 |
| Carcinoma in situ | D002278 | — | D09.9 | — | — | — | — | 2 | 2 |
| Atrophy | D001284 | — | — | — | — | — | — | 2 | 2 |
| Motor activity | D009043 | EFO_0003940 | — | — | — | — | — | 2 | 2 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 1 | 1 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | — | 1 | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | — | — | 1 | 1 |
Show 47 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Interferon beta |
| INN | interferon beta |
| Description | The type-I interferons (IFN) are cytokines which play essential roles in inflammation, immunoregulation, tumor cells recognition, and T-cell responses. In the human genome, a cluster of thirteen functional IFN genes is located at the 9p21.3 cytoband over approximately 400 kb including coding genes for IFNα (IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17 and IFNA21), IFNω (IFNW1), IFNɛ (IFNE), IFNк (IFNK) and IFNβ (IFNB1), plus 11 IFN pseudogenes.
|
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >4CNI:A,H|OLOKIZUMAB HEAVY CHAIN, FAB PORTION
EVQLVESGGGLVQPGGSLRLSCAASGFNFNDYFMNWVRQAPGKGLEWVAQMRNKNYQYGTYYAESLEGRFTISRDDSKNS
LYLQMNSLKTEDTAVYYCARESYYGFTSYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVS
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVES
>4CNI:B,L|OLOKIZUMAB LIGHT CHAIN, FAB PORTION
DIQMTQSPSSLSASVGDRVTITCQASQDIGISLSWYQQKPGKAPKLLIYNANNLADGVPSRFSGSGSGTDFTLTISSLQP
EDFATYYCLQHNSAPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Target
Agency Approved
IL6R
IL6R
IL6
IL6
Alternate
IFNAR1
IFNAR1
Organism
Homo sapiens
Gene name
IFNAR1
Gene synonyms
IFNAR
NCBI Gene ID
Protein name
interferon alpha/beta receptor 1
Protein synonyms
alpha-type antiviral protein, beta-type antiviral protein, CRF2-1, Cytokine receptor class-II member 1, Cytokine receptor family 2 member 1, IFN-alpha/beta receptor 1, IFN-R-1, IFNalpha/beta receptor 1, interferon (alpha, beta and omega) receptor 1, interferon receptor 1, interferon-alpha/beta receptor alpha chain, interferon-beta receptor 1, Type I interferon receptor 1
Uniprot ID
Mouse ortholog
Ifnar1 (15975)
interferon alpha/beta receptor 1 (Q80UJ3)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Avonex – Biogen
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 47,513 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
232,949 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use